Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $2.64M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
SAN RAFAEL, CA 94903
SAN RAFAEL, CA 94903
33aNPI1194895227assigned 11/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.64M
24GClaims66,244
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#251 of 410
Median peer was paid$6.90M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,303 | $60K | |
| 2019 | 3,271 | $68K | |
| 2020 | 3,473 | $70K | |
| 2021 | 4,208 | $88K | |
| 2022 | 5,772 | $118K | |
| 2023 | 7,424 | $142K | |
| 2024incomplete | 39,793 | $2.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 645 | 600 | $662K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 3,798 | 3,355 | $593K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 879 | 842 | $360K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 13% | 4,538 | 4,032 | $347K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.8% | 869 | 839 | $100K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 194 | 189 | $93K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 319 | 303 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 5,341 | 4,429 | $32K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 920 | 874 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 209 | 203 | $31K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 274 | 266 | $28K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 3,420 | 2,786 | $28K |
75 more codes
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 181 | $26K |
| 76830 | Ultrasound, transvaginal | <1% | 132 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,357 | $21K |
| 80051 | <1% | 3,364 | $18K | |
| 82565 | <1% | 4,422 | $17K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 85 | $13K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 475 | $10K |
| 82947 | <1% | 3,485 | $10K | |
| 84460 | <1% | 2,734 | $10K | |
| 82247 | <1% | 2,459 | $9K | |
| 84520 | <1% | 3,373 | $9K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 54 | $7K |
| 83880 | <1% | 279 | $7K | |
| J3490 | Unclassified drugs | <1% | 1,051 | $7K |
| 84450 | <1% | 2,172 | $7K | |
| 83690 | <1% | 1,448 | $6K | |
| 81001 | <1% | 2,060 | $6K | |
| 84075 | <1% | 1,845 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 281 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 980 | $5K |
| 84702 | <1% | 255 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 152 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 85 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 348 | $3K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 14 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 31 | $3K |
| 83735 | <1% | 652 | $3K | |
| 80061 | Lipid panel | <1% | 192 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 80 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 80 | $3K |
| 85652 | <1% | 689 | $2K | |
| 81003 | <1% | 1,241 | $2K | |
| 0450 | Emergency room services | <1% | 33 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 269 | $2K |
| 76770 | <1% | 13 | $2K | |
| 73110 | <1% | 13 | $2K | |
| 84132 | <1% | 327 | $2K | |
| 85027 | <1% | 247 | $1K | |
| 87088 | <1% | 287 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 398 | $1K |
| 82728 | <1% | 89 | $1K | |
| 85610 | <1% | 415 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 242 | $1K |
| 0637 | <1% | 1,964 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 353 | $1K |
| 84484 | <1% | 359 | $1K | |
| 84100 | <1% | 384 | $1K | |
| 84295 | <1% | 206 | $1K | |
| 82310 | <1% | 187 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $910.49 |
| 85379 | <1% | 128 | $666.42 | |
| 83605 | <1% | 234 | $644.42 | |
| 82077 | <1% | 183 | $639.90 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 303 | $637.79 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 66 | $637.31 |
| 87040 | <1% | 167 | $605.24 | |
| 86140 | <1% | 121 | $593.98 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 32 | $559.21 |
| 84703 | <1% | 265 | $557.37 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 344 | $479.28 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 17 | $463.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 171 | $388.16 |
| 82607 | <1% | 26 | $383.33 | |
| 82040 | <1% | 71 | $339.80 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 252 | $334.10 |
| 80306 | <1% | 25 | $242.64 | |
| 82248 | <1% | 76 | $233.94 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 107 | $191.59 |
| 80178 | <1% | 28 | $150.00 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 111 | $125.20 |
| 85730 | <1% | 12 | $85.34 | |
| 0250 | <1% | 169 | $9.49 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $9.13 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOFFEY, JUDY (SENIOR VICE PRESIDENT, AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Novato, CA | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.